Find an actor
TTC fête ses 10 ans au Campus Biotech30.10.2017Conférence et émission filmée en direct Quand allons-nous mourir ?
Prix Perl 2018Les PERL sont devenus au fil des ans un élément central du soutien de Lausanne Région aux entreprises établies sur...
Tolerys SATherapeutics & Diagnostics, Other
Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Therapeutics & Diagnostics, Vaccines
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.